LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

LEE011

600 mg PO once daily will be given orally on days 1-21 of a 28 day cycle (3 weeks on / 1 week off) :until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason

PROCEDURE

Chemoembolization

Patients will be treated with chemoembolization once every 4 weeks with up to 4 total chemoembolizations within the first 6 months from the initial chemoembolization.

Trial Locations (1)

75390

UT Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER